- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Amgen Executive Discusses Prominent Biosimilar Trends
In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.
Amgen has multiple biosimilars in the marketplace, but also many originator drugs, which puts it on both sides of the scrimmage line.
That gives the company the perspective that policies and regulations designed to stimulate and advance biosimilar competition could be detrimental to the level of innovative investment, as it would potentially make less funding available for biopharmaceutical companies to invest in new drugs, Jen Norton, a vice president and head of US Value & Access for Amgen, says in this interview with Tony Hagen, senior editor for The Center for Biosimilars®. “Oftentimes when you create special legislation to incentivize a particular category over another category, there can be a series of downstream consequences.”
The occasion was Amgen’s presentation of findings from its 2021 Biosimilar Trends Report at the AMCP Nexus 2021 meeting this week at the Gaylord Rockies in Denver, Colorado. Norton authored the report.
Biosimilar market share gains have been strongest in the oncology space, where biosimilars emerged just in the past few years. “It’s really been impressive to see how biosimilars have taken a major role within our health care ecosystem," she says.
Some developments ahead may rival or exceed biosimilar accomplishments so far, such as the arrival of adalimumab biosimilars in 2023. Patients will be able to self-administer these, and this expansion of biosimilars into the pharmacy benefit will be a critical, market-changing event, Norton says.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
